The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Today, Moderna sells just two products: its Covid vaccine called Spikevax — a rival to Comirnaty from Pfizer and BioNTech, and Nuvaxovid from Novavax — and the respiratory syncytial virus vaccine ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.